Patient-reported outcomes (PROs) in a real-world setting provide a means for patients with relapsing–remitting multiple sclerosis (RRMS) to share important information about their disease status, quality of life (QoL), drug efficacy, and treatment satisfaction.

AURELIO was a 2-year study that assessed PROs in a Greek cohort of more than 280 patients with RRMS treated with once-daily oral teriflunomide.

Overall, QoL, and disability scores remained stable over the course of the study, while improved treatment satisfaction and efficacy outcomes versus baseline were observed.

Positive benefits of teriflunomide have now been reported in numerous real-world studies, with the AURELIO data highlighting the importance of PROs to facilitate personalized treatment strategies in MS.